Prognostication in young and old patients with Waldenström's macroglobulinemia: importance of the International Prognostic Scoring System and of serum lactate dehydrogenase.
We analyzed 232 patients with previously untreated, symptomatic WM, of whom 10% were < or = 50 years of age and 21% were > 75 years of age. Disease features and response to treatment were similar among age groups. Patients > 75 years of age had significantly shorter survival (OS; 53 months vs. 113 months for those > 50-75 years vs. not reached for patients < or = 50 years of age; P < .001). Despite the fact that 33% of elderly patients died of causes unrelated to WM, disease-specific survival (DSS) was 72 months for patients > 75 years, 120 months for those > 50-75 years and not reached for patients < or = 50 years (P = .001). International Prognostic Scoring System for WM (IPSSWM) could discriminate 3 risk groups with significantly different OS or DSS. The addition of elevated serum lactate dehydrogenase in the IPSS improved the ability of IPSS to identify a group of patients with a significantly worse outcome (median survival, 55 months).
Department of Clinical Therapeutics, University of Athens, School of Medicine, Greece.
Efstathios
E
Kastritis
Konstantinos
K
Zervas
Panagiotis
P
Repoussis
Evridiki
E
Michali
Eirini
E
Katodrytou
Athanasios
A
Zomas
Argiris
A
Simeonidis
Evangelos
E
Terpos
Sossana
S
Delimbassi
Amalia
A
Vassou
Dimitra
D
Gika
Meletios A
MA
Dimopoulos
D000328:Adult; D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D006801:Humans; D007770:L-Lactate Dehydrogenase / Q000097:blood*; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D015996:Survival Rate; D008258:Waldenstrom Macroglobulinemia / Q000175:diagnosis* / Q000201:enzymology / Q000628:therapy
D007770:L-Lactate Dehydrogenase